NCT05568680View on ClinicalTrials.gov

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Ovarian CancerCholangiocarcinoma RecurrentMesothelioma, Malignant
Interventions
BIOLOGICAL

SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR

Autologous T cells Transduced with Mesothelin KIR-CAR

Trial Locations (4)

19104

RECRUITING

University of Pennsylvania, Philadelphia

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

66205

RECRUITING

University of Kansas Cancer Center, Westwood

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Verismo Therapeutics

INDUSTRY

NCT05568680 - SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Biotech Hunter | Biotech Hunter